Palvella Therapeutics (PVLA) Other Operating Expenses (2013 - 2024)
Palvella Therapeutics' (PVLA) quarterly Other Operating Expenses came in at $1.7 million in Q4 2024, up 111.2% year-on-year from $789773.1 in Q1 2024, and up 393.66% on a QoQ basis from -$568000.0 in Q3 2024.
Palvella Therapeutics (PVLA) Other Operating Expenses (2013 - 2024) Analysis & Trends
Palvella Therapeutics (PVLA) has 3 years of Other Operating Expenses data on file, last reported at $1.7 million in Q4 2024.
- On a quarterly basis, Other Operating Expenses rose 111.2% year-over-year to $1.7 million in Q4 2024; TTM through Sep 2025 was $1.7 million, a 110.79% increase from a year earlier, with the FY2024 full-year figure at $1.1 million, down 95.24% from the prior year.
- Other Operating Expenses for Q4 2024 stood at $1.7 million, up from -$568000.0 in the prior quarter.
- Over the last five years, Other Operating Expenses for PVLA reached as high as $14.9 million in Q3 2023 and fell as low as -$14.9 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Palvella Therapeutics | 1.84 Bn | 1.57 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.67 Mn |
| Sep 30, 2024 | -568,000.00 |
| Dec 31, 2023 | -14.89 Mn |
| Sep 30, 2023 | 14.89 Mn |
| Dec 31, 2013 | 7,912.00 |
| Sep 30, 2013 | 5,750.00 |